Anticancer potential of (−)-epicatechin in a triple-negative mammary gland model
Open Access
- 2 September 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 73 (12) , 1675-1682
Abstract
Objectives: The main aim of this work was to analyse the potential tumour growth inhibition effects of (−)-epicatechin (EC). Triple-negative breast cancer (TNBC) is an invasive form of cancer characterized by the absence of progesterone receptor, estrogen receptor and human epidermal growth factor receptor 2. Doxorubicin (DOX) is widely used for its anti-tumour activity. EC belongs to the flavanol subfamily and is a candidate molecule for the adjuvant treatment of cancer due to its antiproliferative activities. Methods: Evaluation of EC effects and pathways involved in a model of TNBC. Key findings: EC inhibited tumour growth as efficiently as DOX (inhibition rates of 74% and 79% for EC and DOX, respectively). The evaluation of adenosine monophosphate-activated protein kinase (AMPK) and Akt phosphorylation and mTOR expression indicates that EC modulates these pathways, resulting in the inhibition of cell proliferation. Additionally, we found an increase in the survival of EC-treated animals compared with control-treated animals. This effect was similar to the effects induced by DOX (survival rates of 44% and 30% for EC and DOX, respectively). Conclusion: EC has antiproliferative properties and increases survival in a model of TNBC. These effects may occur through the modulation of deregulated AMPK and Akt/mTOR signalling pathways.Keywords
Funding Information
- National Institutes of Health (NIH DK98717, AG47326)
This publication has 34 references indexed in Scilit:
- Decline in the Use of Anthracyclines for Breast CancerJournal of Clinical Oncology, 2012
- mTOR Signaling Pathway and mTOR Inhibitors in Cancer TherapyHematology/Oncology Clinics of North America, 2012
- Otto Warburg's contributions to current concepts of cancer metabolismNature Reviews Cancer, 2011
- Increased Expression of P-Glycoprotein Is Associated with Doxorubicin Chemoresistance in the Metastatic 4T1 Breast Cancer ModelThe American Journal of Pathology, 2011
- Antileukemic action of (−)-epicatechin in the spleen of rats with acute myeloid leukemiaFood and Chemical Toxicology, 2010
- Clinicopathological features and treatment strategy for triple-negative breast cancerInternational Journal of Clinical Oncology, 2010
- Phosphoinositide 3‐kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell deathInternational Journal of Cancer, 2007
- Congestive heart failure in patients treated with doxorubicinCancer, 2003
- Mouse 4T1 Breast Tumor ModelCurrent Protocols in Immunology, 2000
- New anthracycline antitumor antibioticsCritical Reviews in Oncology/Hematology, 1991